Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

The Food and Drug Administration (FDA) recently approved a new, non-opioid (non-narcotic) prescription pill, suzetrigine (SUE-zeh-TRY-gene). It will be sold under the brand name Journavx (JOUR-nah-vix ...

The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive pain medicine.

Now, for the first time in over 20 years, the FDA has approved a non-opioid pain ... Dr. Todd Burtoch joins Living Oklahoma to tell us more about Journavx. He's the Chief Medical Officer for ...